Novavax is seeking authorization in the U.K. for its COVID-19 vaccine

Shares of Novavax Inc.
NVAX,
-0.27%
jumped 8.0% in premarket buying and selling on Wednesday after the corporate mentioned it started submitting its experimental COVID-19 vaccine for authorization within the U.Ok. Novavax’s vaccine candidate is protein-based, which means it is a completely different sort of vaccine than the mRNA pictures developed by BioNTech SE
BNTX,
-0.86%
/Pfizer Inc.
PFE,
+0.95%
and Moderna Inc.
MRNA,
-1.09%
or the ChAdOx1 know-how used within the AstraZeneca
AZN,
+0.79%
pictures. Novavax’s vaccine got here out of medical trials within the U.Ok. with an general efficacy charge of 89.7%. The corporate plans to submit its vaccine candidate to U.S. regulators by the tip of the yr. Novavax’s inventory is up 21.0% for the yr, whereas the S&P 500
SPX,
+0.18%
has gained 21.8%.

Source link